Synthesis, characterisation and reactivity of Cu(II) amine complexes supported on an inorganic ion exchanger, zirconium molybdate

771-777Cu(II) amine complexes have been supported onto the surface of an inorganic ion exchanger, zir-conium molybdate. The coordination behaviour of these complexes bound to zirconium molybdate have been studied by TGA, DSC, FTIR, ESR and reflectance spectra. The catalytic activity has been studied through the disproportionation of hydrogen peroxide. The energy of activation (Ea), free energy of activation ( G≠), free enthalpy of activation ( H≠) and free entropy of activation ( S≠) have also been calculated

Use of zirconium tungstate in acid catalysis: Some esterification reactions

803-805Amorphous zirconium tungstate, an inorganic cation exchanger has been prepared. The protons of the hydroxyl groups are the active sites. Such a material indicates good potential for application in Bronsted catalysis. Esterification has been studied as a model reaction wherein ethyl acetate has been synthesized. The variation of several parameters has established the use of zirconium tungstate as a Bronsted acid catalyst

Studies on some oxidation reactions using a Ru(III)supported catalyst

324-328<span style="font-size:11.0pt;line-height: 115%;font-family:Calibri;mso-fareast-font-family:" dejavu="" sans";mso-bidi-font-family:="" mangal;color:#00000a;mso-ansi-language:en-us;mso-fareast-language:en-us;="" mso-bidi-language:ar-sa"="" lang="EN-US">A metal catalyst has been prepared by supporting Ru(III) onto zirconium molybdate to catalyze oxidation reactions. The material has been characterised and the catalytic activity has been studied via hydrogen peroxide decomposition. Further, oxidation of a few organic substrates such as norbornene, cis-cyclooctene, styrene, cyclohexene and cyclohexane have been carried out.</span

A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting

Ketamine, in research settings, rapidly reduces suicidal thoughts 2&ndash;24 h after a single infusion in patients with high suicidal ideation. In this study, the authors investigate ketamine&rsquo;s effects on suicidality in a real-world sample of recent suicide attempters on a tertiary-care Consultation-Liaison (CL) psychiatry service. Using an open-label design, 16 transdiagnostic CL patients were recruited, 18&ndash;65 years old, to receive a single dose of intravenous ketamine (0.5 mg/kg) in the acute medical setting. All were psychiatrically hospitalized post-infusion. Baseline suicidality and depression measures were compared to ratings taken at 24 h, 5 days, 12 days, and 1, 3 and 6 months post-infusion using paired t-tests. Across all measures, rapid, statistically significant decreases (p&rsquo;s &lt; 0.001) were observed with large to very large effect sizes (Cohen&rsquo;s d&rsquo;s: 1.7&ndash;8.8) at acute timepoints (24 h; 5 days). These gains were uniformly maintained to 6 months post-infusion. Open-label ketamine appeared to rapidly and robustly reduced suicidal symptoms in an ultra-high-risk, heterogeneous, real-world sample. Ketamine infusion may therefore be a safe, feasible, viable method to rapidly reduce suicidality among medically hospitalized patients after a suicide attempt, with potentially enduring benefits. The current pilot findings suggest ketamine could be readily integrated into the settings where high-risk CL patients already receive healthcare, with the potential to become an important and novel tool in the treatment of suicidality